{"disease":{"id":"her2-positive-gastroesophageal-junction-adenocarcinoma","name":"her2 positive gastroesophageal junction adenocarcinoma"},"drugs":{"marketed":[{"drug_id":"trastuzumab-deruxtecan","indication_name":"Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enhertu","generic_name":"trastuzumab-deruxtecan","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":63,"revenue":"2900","mechanism":"Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells."},{"drug_id":"enhertu","indication_name":"Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enhertu","company_name":"Washington D.C. Veterans Affairs Medical Center","drug_phase":"marketed","molecular_target":"DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":13,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06764875","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06123494","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05993234","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","phase":"","overall_status":"RECRUITING","enrollment_count":257,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":false},{"nct_id":"NCT04704661","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05218148","title":"SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":44,"lead_sponsor_name":"Aiping Zhou","has_results":false},{"nct_id":"NCT06572319","title":"Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05555251","title":"BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"BioInvent International AB","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}